Does icosapent ethyl 2 g twice daily reduce ischemic events in patients with elevated triglyceride levels despite the use of statins?
Patients with elevated triglyceride levels despite the use of statins
Icosapent ethyl 2 g twice daily
Placebo
Ischemic events, including cardiovascular deathhard clinical
Icosapent ethyl significantly reduces the risk of ischemic events in statin-treated patients with elevated triglycerides.
Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361 .).
Building similarity graph...
Analyzing shared references across papers
Loading...
Deepak L. Bhatt
Philippe Gabríel Steg
Michael Miller
New England Journal of Medicine
Harvard University
Brigham and Women's Hospital
Inserm
Building similarity graph...
Analyzing shared references across papers
Loading...
Bhatt et al. (Sat,) studied this question.
www.synapsesocial.com/papers/69ccf700da2a6987e0cbfbbc — DOI: https://doi.org/10.1056/nejmoa1812792